Servier Presents Promising Phase 1 Data for Emiltatug Ledadotin in Adenoid Cystic Carcinoma
Servier has announced encouraging Phase 1 clinical trial results for Emiltatug Ledadotin (Emi-Le), an investigational antibody drug conjugate (ADC) targeting B7-H4, at the ASCO 2026 Annual Meeting. The trial involved 180 patients with advanced or metastatic solid tumors, including 48 with adenoid cystic carcinoma (ACC). Emi-Le demonstrated a favorable safety profile and promising efficacy, with a 35.6% objective response rate and an 82.2% disease control rate among ACC patients. The U.S. FDA has granted Breakthrough Designation to Emi-Le for treating locally advanced, recurrent, or metastatic ACC, highlighting the critical need for targeted therapies in this patient population. 
